Last updated: August 9, 2023
Sponsor: Alexandra Hospital
Overall Status: Active - Recruiting
Phase
N/A
Condition
Stroke
Cerebral Ischemia
Treatment
EsoGLOVE with Trigno Biofeedback (EMG sensors)
Graded Repetitive Arm Supplementary Program (GRASP)
Clinical Study ID
NCT05995665
2020/01105
Ages 30-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Aged 30-90 years regardless of lesion size, race
- Stroke type: ischemic or haemorrhagic
- Medically stable conditions
- Fugl-Meyer Assessment (FMA) of upper extremity impairment of 10-56 out of 66.
- Able to give own consent, comprehend and follow commands
- Able to sit upright and maintain sitting balance for at least 30 minutes
- Able to stay alert and focus on the tasks at least 30 minutes and more.
- Unilateral upper limb impairment
Exclusion
Exclusion Criteria:
- Recurrent stroke
- Unstable medical conditions (e.g. heart attack, unstable blood pressure, infection,and etc.) or anticipated life expectancy of <1 year.
- Cognitive and communicative impairment (e.g. severe receptive aphasia, inattention,learning difficulty, and etc).
- History of severe depression or active psychiatric disorder.
- Severe spasticity (Modified Ashworth scale ≥2), joint contractures or deformity, poorskin conditions (e.g. irritated skin, open wounds), amputation of fingers, andallergic condition (e.g. patients with allergies to adhesive gel).
- Poor trunk control or postural hypotension.
Study Design
Total Participants: 130
Treatment Group(s): 2
Primary Treatment: EsoGLOVE with Trigno Biofeedback (EMG sensors)
Phase:
Study Start date:
July 11, 2023
Estimated Completion Date:
June 30, 2025
Study Description
Connect with a study center
Alexandra Hospital
Singapore,
SingaporeActive - Recruiting
Jurong Community Hospital
Singapore,
SingaporeActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.